尼达尼布治疗结缔组织相关性间质性肺炎临床疗效研究
Clinical efficacy of Nintedanib in the treatment of connective tissue-associated interstitial pneumonia
向玉 1曾宪升 2姚香萍 2张帆1
作者信息
- 1. 武汉科技大学医学部医学院,湖北武汉 441021
- 2. 襄阳市中心医院呼吸与危重症医学二科,湖北襄阳 441021
- 折叠
摘要
目的:评估尼达尼布联合常规治疗对结缔组织相关性间质性肺炎(CTD-ILD)的疗效.方法:收集102例CTD-ILD患者作为研究对象,根据临床治疗方案不同将其分为常规治疗组(50例)和尼达尼布联合治疗组(52例),疗程6个月.比较2组患者治疗前、治疗6个月后临床症状、肺功能、肺部高分辨CT评分及血清细胞因子水平的变化.结果:尼达尼布联合治疗组血清细胞因子、肺部高分辨CT评分较治疗前明显降低,肺功能明显改善(P均＜0.05).结论:尼达尼布联合常规糖皮质激素抗炎治疗可降低CTD-ILD患者血清细胞因子水平,减轻体内炎症反应,改善肺功能,有助于延缓CTD-ILD患者的肺纤维化进展.
Abstract
Objective:To evaluate the efficacy of Nintedanib combined with conventional treatment for connective tissue-associated interstitial pneumonia(CTD-ILD).Methods:A total of 102 patients with CTD-ILD were collected and divided into conventional treatment group(50 cases)and Nintedanib combined treatment group(52 cases)for 6 months according to different clinical treatment plans.The changes of clinical symptoms,lung functions,high resolution CT scores and serum cytokine levels were compared before and 6 months after treatment in 2 groups.Results:The serum cytokines and lung high resolution CT scores in Nintedanib combined treatment group were significantly lower than those before treatment,and the lung function was significantly improved(all P＜0.05).Conclusion:Nintedanib combined with conventional glucocorticoid anti-inflammatory therapy can reduce serum cytokine levels in CTD-ILD patients,reduce inflammation in vivo,improve lung function,and help delay the progression of pulmonary fibrosis in CTD-ILD patients.
关键词
结缔组织相关性间质性肺炎/尼达尼布/细胞因子Key words
Connective tissue-associated interstitial pneumonia/Nintedanib/Cytokine引用本文复制引用
基金项目
湖北省卫生健康委员会项目(WJ2023F071)
出版年
2024
NETL
NSTL
万方数据